Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Rutgers, The State University Of New Jersey, , New Jersey Institute Of Technology patent solves the following problem:

Luminescent lanthanide chelates has become the main objective of the investigation was because of their unique spectral properties (Gudgin Dickson et al (1995) Pharmac Father 66: ….. 207-235; Selvin, PR (2002) Annu Rev Biophys Biomol . Strutt 31: 275-302, and HEMMILA et al (2005) J. Fluoresc 15 :. 529-542) … these molecules used in a wide variety of biochemical assays, including, for example -ingnan, medical diagnostics, drug discovery, and as imaging tools in cell biological applications. Luminescent lanthanide chelates are especially useful as non-isotopic alternatives to conventional organic fluorophores in applications where high background fluorescence is an issue. The unique spectral (ie, sharply spiked top) and temporal (ie, long-lasting emissions) property luminescent lanthanide chelates allow (i) ultra-high sensitivity detection (ii) facile, simultaneous monitor some analytes in the same sample mixture, and (iii) the additional information obtained from an individual analyte in a sample.

Our analysis of this patent is as follows:

Rutgers, The State University Of New Jersey, , New Jersey Institute Of Technology’s patent US 9221759 B2 deals with Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency.
The invention relates to novel luminescent composition of matter containing a fluorophore, artificial methods of making the composition, macromolecular conjugates of the composition, and the use of the composition of various detection methods. invention also provides kits containing compositions and their conjugates for use in the detection methods.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Laser source assembly with thermal control and mechanically stable mounting

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Daylight Solutions, Inc. patent solves the following problem:

Anti-aircraft missiles can be used to attack and destroy the target plane, while not need enemies getting too close to the target to target. Moreover, anti-aircraft missiles are often included in a guidance system that makes the anti-aircraft missile to be locked to the target plane even attempted evasive maneuvers to target planes. Thus, the party attacked needs to improve the way they can avoid and / or lack of anti-aircraft missiles. A means for disabling the anti-aircraft missiles is to develop reliable and cost-effective ways to jam or lack the guidance system of anti-aircraft missile. For example, the party attacked can use a proper generated and directed laser beam from a laser source to jam or otherwise lack the guidance system of anti-aircraft missile.

Our analysis of this patent is as follows:

Daylight Solutions, Inc.’s patent US 9225148 B2 deals with Laser source assembly with thermal control and mechanically stable mounting.
A laser source (340) comprising a first frame (356), a laser (358), and a first mounting assembly (360). The laser (358) generates an output beam (354) directed along a beam axis (354A). The first mounting assembly (360) allowing the laser (358) to expand and contract relative to the first frame (356) along a first axis and along a second axis that is orthogonal to the axis beams, while maintaining alignment of the output beam (354) so ​​that the beam axis (354A) is substantially coaxial with the first axis. The first mounting assembly (360) may include a first fastener assembly (366) that couples the laser (358) in the first frame (356), and a first alignment assembly (368) which maintains compliance the laser (358) by a first adjustment axis (370) substantially parallel to the first axis.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Anti-GPR49 monoclonal antibodies

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Bionomics Inc. patent solves the following problem:

G-protein-coupled receptor 49 (GPR49), also known as LGR5 / HG38 / FEX, of the leucine-rich repeat containing G protein-coupled receptor (LGRs) structurally similar to the glycoprotein hormone receptor. LGRs divided into three subgroups: (1) glycoprotein hormone receptor and the thyroid-stimulating hormone (TSH) receptor, follicle-stimulating hormone (FSH) receptor, and luteinizing hormone (LH) receptor; (2) relaxin receptor LGR7 and LGR8; and (3) GPR48, GPR49, and LGR6. GPR49 is expressed in several tissues including the intestines, skeletal muscle, placenta, brain, and spinal cord. However, little is known about the function of GPR49.

Our analysis of this patent is as follows:

Bionomics Inc.’s patent US 9221907 B2 deals with Anti-GPR49 monoclonal antibodies.
Pictured here is the antibody against GPR49 and use of such antibody. Various aspects related to monoclonal, humanized, or fully human antibody against GPR49, hybridomas or other cell lines expressing the antibody, nucleic acid and the vector comprising nucleic acid encoding such antibody.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods of inhibiting solid tumor growth by administering GPR49 antibodies

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Bionomics Inc. patent solves the following problem:

G-protein-coupled receptor 49 (GPR49), also known as LGR5 / HG38 / FEX, of the leucine-rich repeat containing G protein-coupled receptor (LGRs) structurally similar to the glycoprotein hormone receptor. LGRs divided into three subgroups: (1) glycoprotein hormone receptor and the thyroid-stimulating hormone (TSH) receptor, follicle-stimulating hormone (FSH) receptor, and luteinizing hormone (LH) receptor; (2) relaxin receptor LGR7 and LGR8; and (3) GPR48, GPR49, and LGR6. GPR49 is expressed in several tissues including the intestines, skeletal muscle, placenta, brain, and spinal cord. However, little is known about the function of GPR49.

Our analysis of this patent is as follows:

Bionomics Inc.’s patent US 9221906 B2 deals with Methods of inhibiting solid tumor growth by administering GPR49 antibodies.
Pictured here is the antibody against GPR49 and with the same antibody. Various aspects related to monoclonal, humanized, or fully human antibody against GPR49, hybridomas or other cell lines expressing the antibody, nucleic acid and the vector comprising nucleic acid encoding for these antibodies, and methods of treating cancer such antibody.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods for producing immunobinders of cell-surface antigens

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Esbatech, An Alcon Biomedical Research Unit Llc patent solves the following problem:

Immunobinders, including antibodies, their conjugates and origin of the hugely commercially important therapeutic and diagnostic agents. Traditional methods for antibody preparation or screening often use to dissolve antigens. But, for some membrane-bound protein antigens, the conformational epitopes on antigens that changed when the antigens were solubilized from the membrane, resulting in the failure of antibody preparation or screening. Moreover, a major problem at the immunoblotting and affinity chromatography methods is that the antibody with a moderate affinity for the antigen of choice. It allows the inclusion of many cross-reactive antibody or sticky, causing the ship in a series of screening procedures. Although cells expressing membrane-bound antigens used for antibody preparation, an efficient screening method capable of and develop high affinity antibody against cell-surface antigens still lacking.

Our analysis of this patent is as follows:

Esbatech, An Alcon Biomedical Research Unit Llc’s patent US 9221905 B2 deals with Methods for producing immunobinders of cell-surface antigens.
invention provides methods for identifying immunobinders, as scFv antibody can specifically bind to the small surface antigens, and compositions identified by said methods.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Treatment of osteoarthritis using IL-20 antagonists

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The National Cheng Kung University patent solves the following problem:

Osteoarthritis, also known as degenerative arthritis or degenerative joint disease, is the most common form of arthritis, affecting millions of people worldwide. It is characterized by cartilage breakdown, subchondral sclerosis, osteophyte formation, and again to the joint capsule, which led to the destruction of joints. Osteoarthritis is age-related. Physician-diagnosed arthritis occurs in more than 50% of adults older than age 65 years, and more than 30% of adults aged 45-64 years. Valdes et al, Best Practice & Research Clinical Rheumatology, 24 (1) :. 3-14; 2010.

Our analysis of this patent is as follows:

National Cheng Kung University’s patent US 9221904 B2 deals with Treatment of osteoarthritis using IL-20 antagonists.
The present disclosure provides methods for alleviating or delaying the onset of osteoarthritis in a subject in need of treatment with an IL-20 antagonists, to be an antibody that blocks a signal path mediated IL-20, for example, an anti-IL -20 antibody.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Combinatorial antibody libraries and uses thereof

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Fabrus, Inc. patent solves the following problem:

Many therapeutic and diagnostic monoclonal antibodies (mAbs) were used in the clinical setting to treat and diagnose human diseases, for example, cancer, and autoimmune diseases. For example, the ideal therapeutic antibody include Rituxan (Rituximab), Herceptin (Trastuzumab), Avastin (Bevacizumab) and Remicade (Infliximab). In designing antibody therapeutics, it is desirable to make antibody, for example, antibodies that modulate the functional activity of a target, and / or increased antibody as the antibody with higher specificity and / or affinity and / or the antibodies that are more bioavailable, or strong or melt the particular cellular or tissue environment.

Our analysis of this patent is as follows:

Fabrus, Inc.’s patent US 9221902 B2 deals with Combinatorial antibody libraries and uses thereof.
Methods for making a combinatorial antibody library of human part germline given. Provided that the libraries of nucleic acid molecules compiled from the germline of encoding VL chains and libraries of nucleic acid molecules encoding VH chains, and the resulting antibody library. The library is given as addressable libraries. Methods for screening antibody library against a target protein antigen, and the identified or selected antibody given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods of treating complement-associated disorders with anti-C5a antibodies

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Alexion Pharmaceuticals, Inc. patent solves the following problem:

The complement system works with other immunological systems of the body to protect against the entry of cellular and viral pathogens. There are at least 25 complement proteins, which are seen as a complex collection of plasma proteins and membrane cofactors. The plasma proteins make up 10% of the globulins in vertebrate serum. Complementary components achieve their immune defensive functions by interacting in a series of intricate but precise enzymatic cleavage and membrane binding events. The resulting complement cascade leads to the production of products with opsonic, immunoregulatory, and lytic functions. A brief summary of the biological activities associated with complement activation given, for example, in The Merck Manual, 16th Edition.

Our analysis of this patent is as follows:

Alexion Pharmaceuticals, Inc.’s patent US 9221901 B2 deals with Methods of treating complement-associated disorders with anti-C5a antibodies.
The present disclosure relates to, inter alia, the antibody, or antigen-binding fragments thereof, that bind to C5a and the use of the antibody in methods for treating or preventing complement-associated disorders such as, but not limited , atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burns, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods for identifying safe and functional humanized antibodies

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Ac Immune S.A., , Genentech, Inc. patent solves the following problem:

Amyloidosis is a disease entity but rather a diverse group of progressive disease processes characterized by extracellular tissue deposits of a waxy, starch-like protein called amyloid, which accumulates in one or more organs or body systems. As the amyloid deposits accumulate, they begin to interfere with the normal function of the body organ or system. There are at least fifteen different types of amyloidosis. The major forms are primary amyloidosis without known antecedent, secondary amyloidosis following some other condition, and the inheritance amyloidosis.

Our analysis of this patent is as follows:

Ac Immune S.A., , Genentech, Inc.’s patent US 9221900 B2 deals with Methods for identifying safe and functional humanized antibodies.
The present invention relates to safe and functional antibody for therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Therapeutic CD47 antibodies

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Vasculox, Inc. patent solves the following problem:

Our analysis of this patent is as follows:

Vasculox, Inc.’s patent US 9221908 B2 deals with Therapeutic CD47 antibodies.
If the monoclonal antibody and antigen-binding fragments thereof that here, and inhibits the activity of CD47, as well as monoclonal antibody and antigen binding fragments thereof that compete with former for binding to CD47. It also gives the activity of any of the foregoing. The antibody compounds are various effective at 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other times of operation and / or trauma that IRI is a component in the pathogenesis; 2) the treatment of autoimmune and inflammatory diseases; and 3) as anti-cancer agent that is toxic to cancer cells dangerous, improve their phagocytic uptake and clearance, or directly killing the cells.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.